Selected data models

You must log in to select data models for download or further analysis.

111 Search results.
Relevance Rating New first Old first

dbGaP phs000502 Genome-Wide Analysis of Splenic Marginal Zone Lymphoma - pht002815.v1.p1

- 12/13/22 - 4 forms, 1 itemgroup, 5 items, 1 language
Itemgroup: pht002815
Principal Investigator: Laura Pasqualucci, MD, Institute for Cancer Genetics, Columbia University, New York, NY, USA MeSH: Lymphoma, Non-Hodgkin,Lymphoma, B-Cell https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000502 Splenic Marginal Zone Lymphoma (SMZL) is a B-cell malignancy of unknown pathogenesis and thus orphan of targeted therapies. By integrating whole-exome sequencing and copy-number analysis of 8 paired tumor-normal DNAs from patients with SMZL, we show that the typical SMZL exome carries ~30 genetic alterations. Targeted resequencing of selected candidates in an extended panel of 40-117 samples revealed activating mutations of NOTCH2, a gene required for marginal-zone (MZ) development, as the most frequent and SMZL-specific lesion, accounting for approximately 20% of cases. Additional altered genes suggest that deregulation of signaling pathways normally involved in MZ development (NOTCH, NF-kappa B, and B-cell receptor) represents a critical event in SMZL pathogenesis. These findings have direct implications for the treatment of SMZL patients since drugs are available which can target NOTCH as well as other pathways deregulated in this disease.

Eligibility

1 itemgroup 2 items

pht002814.v1.p1

1 itemgroup 3 items

pht002813.v1.p1

1 itemgroup 2 items

Eligibility Mature B-Cell Lymphoma NCT01046825

- 9/27/21 - 1 form, 2 itemgroups, 25 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Mature B-Cell Lymphoma And Leukemia Study III; ODM derived from: https://clinicaltrials.gov/show/NCT01046825

Screening Demographics GOAL Trial B-cell Lymphoma NCT02499003

- 9/20/21 - 1 form, 1 itemgroup, 6 items, 1 language
Itemgroup: Demographics
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Study part: Demographics (Screening) Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Screening Biopsy GOAL Trial B-cell Lymphoma NCT02499003

- 9/20/21 - 1 form, 3 itemgroups, 22 items, 1 language
Itemgroups: Admininstrative data, Bone marrow biopsy, Biopsy Tumor
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Screening Serology GOAL Trial B-cell Lymphoma NCT02499003

- 9/20/21 - 1 form, 1 itemgroup, 8 items, 1 language
Itemgroup: Serology Viral
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Visit: Screening. Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Biopsy GOAL Trial B-cell Lymphoma NCT02499003

- 9/20/21 - 1 form, 1 itemgroup, 13 items, 1 language
Itemgroup: Biopsy
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma. Visit: End of Treatment. Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - History of Lymphoma

- 9/20/21 - 1 form, 5 itemgroups, 21 items, 1 language
Itemgroups: Administrative Data, Cell Type, Grade, Extranodal Involvement at Enrollment, CD20 Reactivity
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Eligibility Lymphoma, B-Cell NCT00515138

- 9/20/21 - 1 form, 2 itemgroups, 21 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant; ODM derived from: https://clinicaltrials.gov/show/NCT00515138

Interim-PET and Randomisation PETAL Study NCT00554164 - Interim-PET and Randomisation

- 9/20/21 - 1 form, 4 itemgroups, 15 items, 2 languages
Itemgroups: Interim-PET und Randomisation, PET, Stratification criteria, Footer module
Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (PETAL-Studie) Universitätsklinikum Essen (UK Essen) EudraCT-Nummer: 2006-001641-33 NCT00554164

NCT01193842 On-Study - AMC-075 Baseline Lymphoma Disease Activity and Assessment Form (LAA) - 3206533v1.0 - AMC-075 Baseline Lymphoma Disease Activity and Assessment Form (LAA)

- 9/20/21 - 1 form, 5 itemgroups, 20 items, 1 language
Itemgroups: Header Module, Lymphoma Disease Activity and Assessment, Histogenetic subtyping markers, Lymphatic Involvement, Comments
AMC-075 Baseline Lymphoma Disease Activity and Assessment Form (LAA) Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With Previously Untreated HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9F16C635-12A6-DD97-E040-BB89AD43743A

Eligibility Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma NCT01514344

- 6/22/21 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01514344

Eligibility Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma NCT01514344

- 6/20/21 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01514344

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial